Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 17879919.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.
Medical subject headings
- Antibodies, Monoclonal
- Antiviral Agents
- Hematologic Diseases
- Hematopoietic Stem Cell Transplantation
- Respiratory Syncytial Virus Infections
- Respiratory Tract Infections